[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525604":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":91,"collaborators":95,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":10,"eligibilityCriteria":11,"healthyVolunteers":107,"sex":108,"minAge":10,"maxAge":10,"enrollmentInfo":109,"targetDuration":112,"studyType":113,"phases":10,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Central South University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Individuals with schizophrenia",null,"Inclusion Criteria:\n\n* 1.Clinical diagnosis of schizophrenia according to ICD-11.\n* 2.Confirmation of the diagnosis of schizophrenia using the SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).\n\nExclusion criteria:\n\n* 1.Clinical diagnosis or SCID-5-RV assessment confirming neurodevelopmental disorders, bipolar and related disorders, substance use disorders (excluding alcohol and tobacco).\n* 2.Presence of severe or acute physical illnesses, including traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular diseases, acute respiratory system diseases, acute hematological disorders, etc.\n* 3.Presence of clearly defined genetic diseases, including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47,XXY), etc.",[13],"Other: Regular follow-up assessments without intervention.",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy volunteers","* Inclusion Criteria:\n\n  1. Ages 13-60 years old.\n  2. Clinical diagnosis not meeting ICD-11 criteria for schizophrenia.\n  3. Diagnosis not meeting schizophrenia criteria confirmed using SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).\n* Exclusion criteria are the same as for the schizophrenia patient group.",[18],"Other: Cross-sectional assessment",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Regular follow-up assessments without intervention.","Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, half a month, 1st month, 3rd months, 6th months, 9th months and 12th months. Baseline assessments will include demographic information, medical history, and previous medication use. For participants on antipsychotics at baseline, the Simpson-Angus Scale for extrapyramidal symptoms(SAS) will also be administered. At baseline and each follow-up, data on current medication, physical examination, anthropometry, ECG, EEG, psychiatric scales (PANSS, CGI, GAF, PSP, SAS, TESS, MMAS-8), the MATRICS Consensus Cognitive Battery, and laboratory tests (blood routine, liver and renal function, lipids, fasting glucose, fasting insulin, HbA1c) will be obtained, alongside fMRI, eye movement, and fNIRS measures. Blood samples will be collected and stored for mechanistic investigations.",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Cross-sectional assessment","Volunteers will undergo assessments, including SCID scale, SCL-90, Chinese Perceived Stress Scale(CPSS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.",[15],[29],{"name":30,"affiliation":31,"role":32},"Renrong Wu, M.D., Ph.D.","Mental Health Institute of Second Xiangya Hospital,CSU","STUDY_CHAIR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","15874179855","wurenrong2013@163.com",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Hui Tang, M.D.","15802686545","tanghuicsu@163.com",[43,56,66,81],{"facility":44,"status":45,"city":46,"state":47,"zip":10,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":10},"Anhui Mental Health Center","ACTIVE_NOT_RECRUITING","Hefei","Anhui","China","CN",{"type":51,"coordinates":52},"Point",[53,54],117.28083,31.86389,{"lat":54,"lon":53},{"facility":57,"status":45,"city":58,"state":59,"zip":60,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450052",{"type":51,"coordinates":62},[63,64],113.64861,34.75778,{"lat":64,"lon":63},{"facility":31,"status":67,"city":68,"state":69,"zip":70,"country":48,"countryCode":49,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"RECRUITING","Changsha","Hunan","410011",{"type":51,"coordinates":72},[73,74],112.97087,28.19874,{"lat":74,"lon":73},[77,79],{"name":78,"role":35,"phone":36,"phoneExt":10,"email":37},"Renrong Wu, PhD, M.D",{"name":80,"role":35,"phone":40,"phoneExt":10,"email":41},"Hui Tang, M.D",{"facility":82,"status":45,"city":83,"state":84,"zip":85,"country":48,"countryCode":49,"cosmosGeoPoint":86,"geoPoint":90,"contacts":10},"Nanjing Brain Hospital, Nanjing Medical University","Nanjing","Jiangsu","210029",{"type":51,"coordinates":87},[88,89],118.77778,32.06167,{"lat":89,"lon":88},{"type":92,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Renrong Wu","Professor",[96,97,100],{"name":57,"class":6},{"name":98,"class":99},"The Affiliated Brain Hospital of Nanjing Medical University","OTHER_GOV",{"name":44,"class":101},"UNKNOWN","100525604","establishing-a-clinical-database-and-biobank-for-schizophreniaa-cohort-study-100525604",false,"NCT06123897","Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study",true,"ALL",{"count":110,"type":111},2000,"ESTIMATED","1 Year","OBSERVATIONAL","This is a multicenter study conducted in collaboration with Central South University, The First Affiliated Hospital of Zhengzhou University, Nanjing Brain Hospital of Nanjing Medical University, and Anhui Mental Health Center. The project intends to employ standardized diagnostic criteria and clinical assessment procedures to establish a comprehensive cohort of patients with schizophrenia, encompassing all age groups and disease stages, with follow-up periods exceeding one year. The goal is to create an internationally high-standard clinical cohort database and biobank for schizophrenia. Through a multidimensional assessment framework, the project aims to further investigate the etiology of schizophrenia, patterns of disease progression, and clinical outcomes. By periodically capturing dynamic information on risk and preventive factors, the project aims to achieve early diagnosis, early treatment, and improved prognosis for patients. Additionally, it seeks to explore potential biomarkers within the realm of precision medicine that can predict treatment efficacy, providing viable tools for precision healthcare and clinical decision-making in the field of schizophrenia.",[116],"Schizophrenia",[118],"Schizophrenia, Cohort Study","2024-11-21",{"date":121,"type":122},"2024-11-25","ACTUAL",{"date":124,"type":122},"2024-01-01",{"date":126,"type":111},"2028-12-31",{"name":5,"class":6},4]